Plain-English translation of NCT07359482 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether , a medication commonly used to treat depression and anxiety, can help reduce severe fatigue and other symptoms that persist after COVID-19. Researchers will compare this medication to a placebo (a dummy pill with no active ingredient) over 12 weeks in 160 people with long COVID. The trial will also look at blood markers and brain imaging to understand how the treatment might work.
Many people develop severe, lasting fatigue and cognitive problems after COVID-19 that significantly affect their quality of life, and current treatment options are limited. Researchers believe this medication may help by targeting inflammation and chemical imbalances in the brain that may contribute to long COVID symptoms.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will take either the medication or a placebo pill once daily for 12 weeks. You'll complete online questionnaires about your symptoms and have video calls with the research team to check on how you're doing. Some participants may also be invited to have optional brain imaging scans at a hospital in Amsterdam to help researchers understand how the treatment affects the brain.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Netherlands